Navigation Links
Amsterdam Molecular Therapeutics Announces Negative Equity Position
Date:12/14/2011

AMSTERDAM, December 15, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has a negative equity position, as a result of ongoing loss-making operations. The development of this negative equity position is in line with previous guidance that the Company has cash into early 2012, and is exploring alternatives for additional financing.

AMT announced on November 17, 2011 that its cash position at September 30, 2011 amounted to € 3.8 million, and AMT continues to be loss making and to experience net cash outflows. At December 12, 2011 AMT's cash position amounted to € 2.1 million; AMT does not have any loan, credit or other borrowing facilities other than the € 5 million convertible loan issued in December 2009.

The Company continues partnering discussions with pharma companies. At this time, AMT anticipates that it may be possible to conclude a partnership for its hemophilia B program during the first half of 2012, provided that additional funding can be secured in the meantime. AMT is also looking at additional collaborations with academic groups, which would contribute towards the short-term funding of its GDNF program for up to three indications.

AMT is continuing to explore all options with regard to the business, its financing, and support from existing shareholders. This includes selling all or part of the business, and raising additional capital in conjunction with its bankers and investors. AMT is also tracking opportunities for funding, from non-dilutive sources such as grants, and collaborations with partners. The Company has already taken appropriate action to reduce its costs, and the number of employees has decreased by approximately 50 per cent to 45 staff. Further cost reductions are possible but the savings would not provide a significantly longer runway for seeking a funding solution. Additional reductions m
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
2. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
3. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
5. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... solutions, today announced its GHS Label Guide . To align chemical container ... (GHS), this guide includes explanations of label components, an example of an accurate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation ... combination products , in particular, drug/device combinations. The current system received a score of ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... a recent BusinessWeek article profiling the significant rise ... point out that it is true product innovation through focused ... confidence and resulting market valuation. , ,While Genentech had revenues ... hit $74.2 billion. , ,This surpasses Amgen's top position of ...
... British are interested in bio and life science investments ... Wisconsin. Meanwhile the University of Wisconsin-Madison is introducing two ... April 30, 2005 Listen to this ... discussed with companies in Madison ...
... Inc. has updated its MailFoundry line of ... on OEM hardware instead of using a Sun platform, the ... as fast as the MailFoundry 1100, according to sales executive ... And the cost, at $2,000, is $500 less. , ,In ...
Cached Biology Technology:Drug innovation beats marketing, patents and mergers 2
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale ... von BGI veranstaltet und findet vom 22. bis ... , statt. Die Konferenz ... ihrem Start 2006 ist die ICG weltweit zu ... geworden. Sie ist eines der dynamischsten, enthusiastischsten und ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... use their vision for piloting, just like human pilots. ... specialized neurons to stimulate the wing muscles, which let ... these same neurons be used in a sort of ... and Julien Serres have just shown. These biorobotics specialists ...
... times more likely to have a Body Mass Index (BMI) ... and ten-year-olds are five times more likely, according to research ... researchers who studied BMI figures for more than a thousand ... significantly among younger children, but that levels were much more ...
... University of Pittsburgh Cancer Institute's Center for Environmental Oncology ... that mimic the actions of estrogen, the female hormone. ... concentrate chemicals from their habitat within their bodies, these ... way into the region's waterways. , The study, ...
Cached Biology News:Is there a pilot in the insect? 2Is there a pilot in the insect? 320-year study shows significant rise in childhood obesity, especially among girls 2What's in the water? Estrogenic activity documented in fish caught in Pittsburgh's rivers 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Reacts with methylated DNA from plants and vertebrates...
...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: